Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takehito Yamamoto

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
Indian Journal of Thoracic and Cardiovascular Surgery|October 26, 2020
Evaluation of spinal cord protective threshold of serum memantine, an NMDA receptor antagonist, in a rabbit model of paraplegiaNirmal Panthee, Minoru Ono, Takehito Yamamoto, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2023
Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative studyRyo Yamaguchi, Takehito Yamamoto, Koh Okamoto, et al.
Journal of Pharmaceutical Health Care and Sciences|December 9, 2020
Prediction of the permeability of antineoplastic agents through nitrile medical gloves by zone classification based on their physicochemical propertiesToyohito Oriyama, Takehito Yamamoto, Katsuhiko Nara, et al.
BMC Cancer|October 13, 2023
Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective studyKatsuhiko Nara, Takehito Yamamoto, Hiroharu Yamashita, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 9, 2022
Impact of targeted intervention using a collaborative approach for oral third-generation cephalosporins: An interrupted time-series analysisRyo Yamaguchi, Koh Okamoto, Takehito Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences|May 5, 2017
Evaluation of the permeation of antineoplastic agents through medical gloves of varying materials and thickness and with varying surface treatmentsToyohito Oriyama, Takehito Yamamoto, Yoshitsugu Yanagihara, et al.
International Journal of Clinical Oncology|February 6, 2019
Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patternsTakehito Yamamoto, Kenji Kawada, Koya Hida, et al.
Science Translational Medicine|February 20, 2015
NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapyTappei Takada, Yoshihide Yamanashi, Kentaro Konishi, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysisKatsuhiko Nara, Satoru Taguchi, Sebastiano Buti, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 19, 2005
Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazemTakehito Yamamoto, Takahiro Kubota, Takeshi Ozeki, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Indian Journal of Thoracic and Cardiovascular Surgery|October 26, 2020
Evaluation of spinal cord protective threshold of serum memantine, an NMDA receptor antagonist, in a rabbit model of paraplegiaNirmal Panthee, Minoru Ono, Takehito Yamamoto, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2023
Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative studyRyo Yamaguchi, Takehito Yamamoto, Koh Okamoto, et al.
Journal of Pharmaceutical Health Care and Sciences|December 9, 2020
Prediction of the permeability of antineoplastic agents through nitrile medical gloves by zone classification based on their physicochemical propertiesToyohito Oriyama, Takehito Yamamoto, Katsuhiko Nara, et al.
BMC Cancer|October 13, 2023
Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective studyKatsuhiko Nara, Takehito Yamamoto, Hiroharu Yamashita, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 9, 2022
Impact of targeted intervention using a collaborative approach for oral third-generation cephalosporins: An interrupted time-series analysisRyo Yamaguchi, Koh Okamoto, Takehito Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences|May 5, 2017
Evaluation of the permeation of antineoplastic agents through medical gloves of varying materials and thickness and with varying surface treatmentsToyohito Oriyama, Takehito Yamamoto, Yoshitsugu Yanagihara, et al.
International Journal of Clinical Oncology|February 6, 2019
Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patternsTakehito Yamamoto, Kenji Kawada, Koya Hida, et al.
Science Translational Medicine|February 20, 2015
NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapyTappei Takada, Yoshihide Yamanashi, Kentaro Konishi, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysisKatsuhiko Nara, Satoru Taguchi, Sebastiano Buti, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 19, 2005
Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazemTakehito Yamamoto, Takahiro Kubota, Takeshi Ozeki, et al.
Pageof 9